ShareValue scores for CURX: Valuation 55, Quality 51, Growth 60, Health 58.

CURX
NASDAQ

Curanex Pharmaceuticals Inc Common Stock

$0.19(-0.46%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

7% to 17%
Valuation
55
Fair Value
Price vs Value
Quality
51
Moderate
Business Strength
Growth
60
Moderate
Revenue & Earnings
Health
58
Moderate
Financial Stability
Momentum
12
Bearish
Price Trend

Company Details

About

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026